Share: Facebook Twitter LinkedIn
Activity Provided By:

Relias LLC

Anti-EGFR and Anti-TROP2 Therapies for NSCLC: Updates from the World Meeting on Lung Cancer

Access Activity

Overview / Abstract:

Target Audience
The target audience for this activity are medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other clinicians managing patients with NSCLC.

Program Overview
Treatment of non-small cell lung cancer (NSCLC) is highly dependent on biomarkers. Epidermal growth factor receptor (EGFR) -targeted therapies have improved outcomes for patients with EGFR-mutated tumors; in addition, improved treatment options are emerging for patients who do not express targetable driver mutations or patients who have relapsed after targeted therapies. Clinicians are invited to join a panel consisting of an expert academic thoracic oncologist and a community practice oncologist to discuss novel targeted therapies, recent trial results, and new drug approvals. Panelists will also discuss treatment alternatives for patients’ progression on standard therapies, and best practices for adverse event management.

Learning Objectives
After completing this activity, the participant should be better able to:

Evaluate recent clinical evidence for anti-EGFR and anti-TROP2 targeted therapies to treat patients with NSCLC
Discuss the integration of clinical updates on anti-EGFR and anti-TROP2 targeted therapies into practice settings

Expiration

Mar 30, 2025

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.0 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty
Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
David Geffen School of Medicine
University of California, Los Angeles (UCLA)

Shahryar Ashouri, MD
Westlake Village Cancer Center
Clinical Professor of Medicine
UCLA Division of Hematology & Medical Oncology

Sponsors / Supporters / Grant Providers

AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Lung Cancer, Anti-EGFR and Anti-TROP2 Therapies Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map